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Iodine contrast nephropathy is the third most com-
mon cause of hospital-acquired acute renal failure.  
With the increasing number of diagnostic and 
interventional procedures, gadolinium-based con-
trast agents (approved by the FDA in 1988) have 
been considered a safe, non-nephrotoxic alternative.  
However, recent studies have described the devel-
opment of nephrogenic systemic fibrosis in patients with renal dysfunction, following 
the use of gadolinium-based contrast agents. 
Nephrogenic Systemic Fibrosis (NSF), previously known as Nephrogenic Fibrosing 
Dermopathy, was first described in 2000; over 300 cases have been reported to date.  
NSF is a systemic disorder that occurs primarily in patients with end stage renal dis-
ease; however, some cases have been reported in patients with moderate renal dys-
function.  It is a debilitating disease that usually affects the skin and joints of the upper 
and lower extremities, causing skin thickening and tightening; these changes may lead 
to impaired mobility and significant morbidity.  The face is generally spared but NSF 
may affect the trunk and internal organs. 
The exact mechanism of the disease is not fully understood; however, exposure to 
gadolinium contrast agents appears to be a major factor, especially in hemodialysis 
patients.  Therapeutic interventions, including oral steroids, extracorporeal photo-
pheresis, plasmapheresis, thalidomide, ultraviolet therapy and intravenous immu-
noglobulin have been used with variable success; renal transplantation is a last resort 
for severe cases.  For pain relief, improved mobility and better outcome, rehabilitation 
therapy should be started as early as possible in all NSF patients. 
As of now, no effective prophylactic measures have been identified.  In 2007, the FDA 
encouraged that gadolinium-containing contrast media be avoided in patients with 
severe renal insufficiency (GFR< 30 ml/min/1.73 m2 ), patients with hepatorenal syn-
drome or patients in the peri-operative liver transplant period.  Although gadolinium 
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administration appears to be a major factor in the development of NSF in patients with severe renal failure, the 
fear of this complication should not eliminate the use of enhanced MRI/MRA when truly indicated. 
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CASE OF THE MONTH 
Divya Gupta MD, Ankit Mehra MD, Emily Coberly MD, James Koller MD 
A 72 year old male presented to the MU Internal Medicine inpatient service with a two month history of fa-
tigue and malaise.  He reported URI symptoms and low grade fevers during this period for which he had been 
seen at several outpatient facilities.  Treatment had included courses of penicillin and Azithromycin with no 
improvement in his symptoms; a strep screen had been negative.  He finally saw his PCP who ordered blood 
cultures, a urine culture and a CXR; when 4 of 4 blood cultures turned positive for gram + coccobacilli, he was 
admitted for further workup. 
His past medical history was remarkable for mitral prolapse, mitral regurgitation, prolactinoma chronic renal 
insufficiency (baseline Cr 1.5) and hypertension.  In 2004, he was treated for mitral valve Strep viridians endo-
carditis with a 4-week course of Penicillin G, followed by ceftriaxone.  Regular meds at the time of his current 
admission included lisinopril, allegra, pravastatin, atenolol and cabergoline; he denied drug allergies.  His 
family history was limited to CHF in his mother.  The patient denied use of alcohol, tobacco or illicit drugs.  He 
was a retired chemical engineer and lived with his wife. 
On admission, he  denied chills, rigors, cough, chest pain, dyspnea, headache, visual change, rashes, joint pain, 
back pain, orofacial pain,  dysuria or hematuria.  He denied preceding travel abroad or insect bites.  His most 
recent dental care was 6 months prior to the onset of his current illness and he took prophylactic penicillin be-
fore that appointment. 
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